… that gefitinib and erlotinib appeared to have similar outcomes in patients with advanced/…
chemotherapy. The overall response rates and disease control rates in the gefitinib- and erlotinib…

… to be the sequela of previous platinum-based chemotherapy. … II trial of erlotinib or standard
chemotherapy in patients with … for patients who developed moderate to severe skin rash on …

… (EGFR) pathway with tyrosine kinase inhibitor (TKI) is an effective and promising salvage
treatment for NSCLC patients who have failed previous chemotherapy, especially for Asian …

… chemotherapy alone after the development of TKI resistance. We found that continuing
erlotinib with chemotherapy … a reasonable treatment option for patients with EGFR‐mutant lung …

… In summary, the findings of this study concur with those of previous research and suggest …
for clinical benefit with erlotinib in patients with NSCLC. Erlotinib suppressed EGFR-mediated …

… The patients had to have received one or two regimens of combination chemotherapy and
not be eligible for further chemotherapy. Patients 70 years of age or older may have received …

… In this meta-analysis, continuous erlotinib plus chemotherapy versus chemotherapy alone
failed to show improvements in PFS and OS. A previous systematic review demonstrated that …

… patients received erlotinib at a fixed oral dose of 150 mg daily and concomitant use of
chemotherapeutic … stage, previous treatments and smoking status was performed on the 108 …

… combination of chemotherapy with erlotinib, followed by erlotinib maintenance therapy. …
administration of erlotinib with chemotherapy has demonstrated promising results in patients with …

… EGFR status measured by immunohistochemistry was not a predictor of tumor response in
previous lung cancer clinical trials with erlotinib or gefitinib, a related EGFR tyrosine kinase …